uniQure N.V.
History
| Year | Detail |
|---|---|
| 1998 | uniQure NV was established as Amsterdam Molecular Therapeutics (AMT) Holding NV by scientists and the Academic Medical Center (AMC) funds. |
| 2012 | uniQure NV's Glybera, an intra-muscular injection, was the Western region's first commercially approved human gene therapy. |
| 2014 | uniQure NV developed a cGMP gene therapy manufacturing unit in Lexington, Massachusetts. |
| 2015 | The company has initiated its phase 1-2 clinical trial of AMT-060 in hemophilia B with AAV5/wtFIX transgene. |
| 2020 | uniQure NV unveiled its license agreement with CSL Behring to commercialize hemophilia B gene therapy. |
| 2022 | uniQure NV has submitted its regulatory filings for hemophilia B gene therapy in the European Union and the US. |
| 2023 | The company received FDA clearance for investigational new drug applications for AMT-260 in Temporal Lobe Epilepsy and AMT-191 in Fabry disease. |
BCC Research Beacon 